Active Stocks
Sat Mar 02 2024 12:49:58
  1. Tata Steel share price
  2. 155.15 3.43%
  1. HDFC Bank share price
  2. 1,430.35 -0.06%
  1. State Bank Of India share price
  2. 773.05 0.49%
  1. Tata Motors share price
  2. 988.40 1.15%
  1. Wipro share price
  2. 522.65 0.67%
Business News/Market/Market Stats/    Nippon India Pharma Fund - Growth

Nippon India Pharma Fund - Growth

+
  • Equity
  • Sector - Healthcare
  • Rating N.A.
  • Plan
426.20 -3.59 (-0.84%) NAV as on 01 Mar, 2024
  • 5D
  • 1M
  • 6M
  • 1Y
  • 5Y
  • MAX

Key Metrics

  • AUM (in Cr)6891.31
  • CAGR 61.13%
  • Exit Load1.00%
  • Expense ratio1.85%
  • CategoryEquity
  • Min Investment5000
  • Min SIP100
  • Launch Date2004-06-05

Morning Star Rating N.A.

Medium
Risk
Exceptional
Return

Asset Allocation

Holdings As On - 03 March 2024

  • Name
  • Value (Cr)
  • Holding %
View More

Risk & Volitility

  • Alpha 5.93%
  • Beta 0.89
  • Sharpe Ratio0.91
  • Std Deviation 15.52%
  • Tracking Error 5.26%

About Fund

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

 

The Nippon India Pharma Fund - Growth has an AUM of 6891.31 crores & has delivered CAGR of 23.65% in the last 5 years. The fund has an exit load of 1.00% and an expense ratio of 1.85%. The minimum investment in Nippon India Pharma Fund - Growth is Rs 5000 and the minimum SIP is Rs 100.

 

As per morningstar the risk & return rating of the fund are Medium & Exceptional respectively.

 

The top holdings of the fund include Sun Pharmaceutical Industries, Lupin, Cipla & Apollo Hospitals Enterprise.

 

The major sectors where the fund is invested are Biotechnology & Drugs, Healthcare Facilities, Major Drugs & Retail (Drugs).

 

Some of the similar funds are DSP Healthcare Fund Regular Growth, ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Growth, Nippon India Pharma Fund - Growth, SBI Healthcare Opportunities Fund Regular Growth, Mirae Asset Healthcare Fund Regular Growth. Nippon India Pharma Fund - Growth has a sharpe ratio of 0.91 & a standard deviation of 15.52%.

FAQs about Nippon India Pharma Fund - Growth

According to the morning star rating Nippon India Pharma Fund - Growth has a Medium risk & Exceptional return.
Nippon India Pharma Fund - Growth is managed by Sailesh Raj Bhan,Kinjal Desai.
The expense ratio of Nippon India Pharma Fund - Growth is 1.85%.
The 5 year annualized return on Nippon India Pharma Fund - Growth is 23.65% & it has generated 61.13% in the last 1 year.
The minimum investment in Nippon India Pharma Fund - Growth is 5000 Rs.
Nippon India Pharma Fund - Growth has an AUM of 6891.31 crores.
Recommended For You